// App-Quantinova.ai

: Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG)

Researchers

Presenter

  • Roman Hajek

Principal Investigators

  • Hans C. Lee

  • Ajai Chari

  • Caitlin L. Costello

  • Noemi Puig

  • Xavier Leleu

  • Jesus G. Berdeja

  • Faith E. Davies

  • Katja Weisel

  • Saad Z. Usmani

  • Vania T. M. Hungria

  • Mario Boccadoro

  • Robert M Rifkin

  • Jeffrey A Zonder

  • Gordon Cook

  • Lucie Broov

  • Magda Barinov

  • Kaili Ren

  • Roxanne Cacioppo

  • Tomas Skacel

  • Dawn Marie Stull

  • Vladimir Maisnar

Medical Centers

  • Department of Neurosurgery, University Hospital Ostrava, Ostrava, Czech Republic

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Mount Sinai School of Medicine, New York, NY

  • Department of Medicine, Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California, San Diego, La Jolla, CA

  • hematology Division, Hospital Universitaro de Salamanca, Salamanca, Spain

  • Pôle Régional de Cancérologie, CHU de Poitiers, Poitiers, France

  • Department of Hematology, Sarah Cannon Research Institute, Nashville, TN

  • Myeloma Institute for Research and Therapy, Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS), Little Rock, AR

  • Universitts-Frauenklinik Tubingen, Tubingen, Germany

  • Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC

  • Department of Hematology, Clinica São Germano and Santa Casa Medical School, São Paulo, Brazil

  • Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy

  • Hematology Research, US Oncology Research, Rocky Mountain Cancer Centers, Yampa Valley Medical Center, United States, Texas

  • Department of Infectious Diseases, Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, MI

  • Haematology, Clinical Trials Research Unit, NIHR (Leeds) IVD Cooperative, Leeds Teaching Hospital, Leeds, United Kingdom

  • Department of Clinical Projects, Institute of Biostatistics and Analyses, Ltd, Brno, Czech Republic

  • Department of Clinical Projects, Institute of Biostatistics and Analyses, Ltd, Brno, Czech Republic

  • Global Statistics and Quantitative Sciences, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Global Outcomes Research,Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited,Cambridge,United States

  • Fourth Department of Internal Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic

Locations

  • Czech Republic

  • Greece

  • United States

  • Spain

  • France

  • Germany

  • Brazil

  • Italy

  • United Kingdom

Companies

  • Millennium Pharmaceu

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Ixazomib

  • Techniclone TNT

Outcome

  • N/A

Study Design

  • Observational

Phase

  • III

Study Id's

  • NCT02761187

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved